Company profile
Dermisonics, Inc.
OTC: DMSI · Healthcare · Medical - Specialties
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 44
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, listing tenure · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$5.1M
Employees
—
as of 2026-07-12
Market cap
$1.9k
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02006
Net income-$5.1M-$5.1M2006
Operating income-$4.5M-$4.5M2006
Total assets$20.1M$20.1M2006
Liabilities$4.5M$4.5M2006
Equity$15.6M$15.6M2006
Revenue trend
FY2003 – FY2006 · USD
FY03
FY04
FY05
FY06
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Dermisonics, Inc.’s revenue?
Dermisonics, Inc. booked $0 in FY2006 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Regnum Corp.——Cotinga Pharmaceuticals Inc.——ForU Holdings, Inc.——Isracann Biosciences Inc.——Legacy Technology Holdings, Inc.——Pure Global Cannabis Inc.——Neighbors
Orange →Key facts
CEOBruce H. Haglund
SectorHealthcare
IndustryMedical - Specialties
HeadquartersIrvine, CA
ExchangeOTC: DMSI
Employees—
IPO date2003-07-11
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.